Biogen’s Tau Drug Slows Alzheimer’s Decline 38% at Two Years, as Real-World Leqembi Data Show 76% Fewer Patients Reaching Moderate Dementia

For most of the past two decades, Alzheimer’s drug development was a story of expensive failures. This week in Boston, at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, the conversation sounded different. Biogen reported that its experimental tau-lowering drug, diranersen, slowed clinical decline by 38% after two years in a mid-stage trial, and on November 18 Biogen and Eisai followed with three-year real-world data suggesting their approved antibody Leqembi keeps far more patients in the early stages of the disease than history would predict.

Neither result is a cure, and both come with important caveats. But together they point to a shift that matters for anyone thinking about healthy aging, family caregiving or the economics of an aging workforce: the field is moving from “can we slow Alzheimer’s at all?” to “how long can we keep people independent?”

What Biogen Reported on Diranersen

According to Biogen’s November 17 release, the 60 mg twice-yearly dose of diranersen slowed decline on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) by 38% at week 96 in the Phase 2 CELIA study, a 1.09-point treatment difference. At 18 months, the same regimen had shown a 26% slowing. The company said the effect grew on five of six measures between 18 months and two years.

  • ADAS-Cog13, a cognition scale: slowing rose from 42% to 54%
  • ADCS-ADL-MCI, which tracks daily activities: from 0% to 30%
  • Modified iADRS: from 30% to 46%
  • MMSE was the exception, easing from 50% to 38%

Diranersen, developed with Ionis Pharmaceuticals, is an antisense drug designed to silence the gene that produces tau, the protein that forms tangles inside brain cells and tracks closely with cognitive decline. Reuters reported that CELIA is the first trial to show that lowering tau can slow Alzheimer’s progression, after a string of failures by other tau-targeting drugs. Side effects were mostly mild to moderate headache or back pain tied to the spinal injection, and there were no reports of the brain swelling associated with amyloid-clearing antibodies.

The caveats are real. BioSpace noted that CELIA missed its primary endpoint, a statistically significant dose response, and that the two-year comparison comes from an open-label extension in which the original placebo group had received no doses or only one dose. Analysts at BMO Capital Markets called the improvement numerical and not statistically significant, while still saying it supports a properly powered study. Biogen told Reuters it is discussing a Phase 3 design with regulators, with results still several years away.

Leqembi’s Real-World Track Record Lengthens

The second piece of news came from the lecanemab side of the field. In a November 18 release, Eisai and Biogen said the ongoing LEADER study of 560 patients at 13 U.S. sites found a 76% lower rate of progression to moderate or severe Alzheimer’s dementia over 36 months compared with a matched natural-history cohort (hazard ratio 0.24). Among 546 patients whose disease stage could be assessed after roughly 18 months of treatment, 81.1% were stable or improved, and 87.5% of all patients were still on therapy.

The companies also said 77% of patients with follow-up scans (33 of 43, across six sites) became amyloid-negative at a median of about 18 months, and that no brain-swelling or bleeding events (ARIA) were reported among 64 patients who moved to the weekly at-home subcutaneous maintenance injection. A day earlier, Eisai reported five-year data from the Clarity AD extension showing that among patients with low tau at the start, 62% improved on the CDR-SB after five years of continuous treatment. Those comparisons rely on external control groups rather than a randomized placebo arm, which is why investigators frame them as supportive rather than definitive.

A Crowded and Mixed Field

Not everything at CTAD went well. BioSpace reported that Priavoid’s oral amyloid drug PRI-002 missed its Phase 2 primary endpoint and that Cognito Therapeutics’ light-and-sound headset failed its Phase 3 HOPE study overall, though the company plans to discuss a path to authorization based on a mild-disease subgroup. South Korea’s AriBio said its oral PDE5 inhibitor AR1001 slowed decline by 31% in a 604-patient monotherapy subgroup of a Phase 3 trial, while missing significance in the full 1,535-patient population.

Why It Matters for Business Readers

Alzheimer’s is as much an economic issue as a medical one. Reuters cited estimates that more than 55 million people worldwide live with dementia, roughly 60% of them due to Alzheimer’s. Every year a person stays in the early stage means more time living independently, fewer hours of unpaid family caregiving and later entry into costly full-time care, which hits employers through absenteeism among working caregivers and hits insurers and pension systems directly.

For investors, the signal is that tau is becoming a credible second front after amyloid. Biogen has said it is already thinking about how Leqembi might be paired with diranersen, either in sequence or in combination, which mirrors the way cancer and HIV care evolved toward multi-drug regimens. The shift toward twice-yearly injections and at-home maintenance dosing also points to a care model that is less dependent on infusion centers, a practical bottleneck that has limited uptake of the first antibody drugs.

For individuals thinking about longevity, the lesson is about timing. Both the low-tau Clarity AD data and the LEADER results suggest the biggest gains come when treatment starts early, which puts more weight on blood-based biomarkers, earlier diagnosis and regular cognitive check-ups as people move into their sixties and seventies.

The Bottom Line

This week’s CTAD data do not prove that any drug can stop Alzheimer’s, and diranersen still has to clear a full Phase 3 trial. But the direction is clear: benefits appear to build the longer patients stay on treatment, and the industry now has two biological targets with clinical evidence behind them. For a disease that has long been defined by how fast it takes independence away, buying patients more years in the early stage is meaningful progress.

Never miss a patient or a caller again. Clinics, home-care agencies and senior-living providers field anxious calls from families at all hours. MAJ.COM Voice AI puts 24/7 AI voice agents on every inbound line and handles outbound follow-ups and customer support, so your business never misses a lead or a family that needs help.

Edited by Coron @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous


Discover more from QUE.com

Subscribe to get the latest posts sent to your email.

Coron @QUE.COM

Editor at QUE.com Intelligence.

coronquecom has 189 posts and counting.See all posts by coronquecom

Leave a Reply

Connect with

Discover more from QUE.com

Subscribe now to keep reading and get access to the full archive.

Continue reading